Chief Executive Officer and Managing Director
Scott joined Mayne Pharma in February 2012. He has more than 30 years of international experience in the pharmaceutical industry and has worked in Europe, the US and Asia. Prior to joining Mayne Pharma, Scott spent ten years in Europe in a variety of leadership roles including President, Europe Middle East and Africa and President, Global Commercial Operations for Mayne Pharma Limited (acquired by Hospira in 2007). He also served on the Group Management Board of Actavis for four years where he was responsible for the firm’s global injectable/hospital business operations. Prior to working in Europe, Scott spent 14 years with FH Faulding and Co (acquired by Mayne Nickless in 2001) in a variety of roles including leading Faulding Pharmaceuticals Asia Pacific operations together with spending five years with Faulding in the United States leading business development and portfolio management operations.
Chief Financial Officer
Peter joined Mayne Pharma in August 2015 as Executive Vice President Corporate and Business Development. Peter has over 20 years of experience in executing public and private mergers and acquisitions and providing strategic advice across a range of contexts and market sectors. In 2020, Peter became Chief Financial Officer and is responsible for group finance along with corporate strategy, M&A, strategic alliances and wider corporate development activities including global business development. He was previously Managing Director of Investment Banking at Credit Suisse Emerging Companies in Australia. Prior to Credit Suisse, Peter was a Director of Hindal Group, a boutique M&A advisory business.
Gerard G. Nahum, M.D.
Chief Medical Officer
Gerard has more than 30 years of clinical and industry experience. He was previously the Vice President of Global Research & Development, Medicare Devices and eHealth at Bayer Pharmaceuticals. He spent more than 15 years at Bayer including as the Head of Global Clinical Development for Women’s Healthcare as well as for other therapeutic areas including Dermatology and Anti-infectives. He also spent two years at the US FDA in the Office of New Drugs at the Center for Drug Evaluation and Research. He is a trained physician who is board-certified in Obstetrics and Gynecology, and he previously served as a professor and residency program director at the Duke University School of Medicine before entering the pharmaceutical industry.
President, Mayne Pharma USA
John joined Mayne Pharma in December 2013 as Executive Vice President of Metrics Contract Services. In January 2017, John became President of Mayne Pharma USA with responsibility for all US operations including manufacturing, quality, supply chain and business integration. He has more than 20 years of experience in the pharmaceutical industry across finance, sales, operations and supply chain. Prior to joining Mayne Pharma, John was a Principal at Tunnell Consulting, a leading US biotech and pharmaceutical consulting organisation.
He has also held a number of leadership roles including Chief Operating Officer of Contract Pharmaceuticals Limited, a provider of outsourced third-party contract development, manufacturing and testing of pharmaceuticals.
President, International Operations
Stefan joined Mayne Pharma in November 2012 and brings more than 25 years of pharmaceutical industry experience to his role. In 2013, Stefan became President of Mayne Pharma USA, relocating to Raleigh, North Carolina to lead the US business operations. In January 2017, Stefan returned to Australia and is now responsible for all non-US operations and commercial activities. Prior to joining Mayne Pharma, Stefan was Head of Marketing (Asia Pacific) for Hospira Inc. (now part of Pfizer), where he was responsible for expansion of the new product portfolio and on-market product growth across all markets in the region. Prior to joining Hospira, Stefan worked for six years with Mayne Pharma Limited in Europe and Australia and eight years with F H Faulding & Co across strategy, business development/M&A, sales and marketing, HR and finance/IT.
Executive Vice President, Corporate Development
Brant joined Mayne Pharma in October 2018 and has more than 25 years of experience in the pharmaceutical industry including more than 15 years at Galderma Laboratories, a leading global dermatology and skin health company. Previously, he was Vice President and General Manager Dermatology at Sandoz US where he was responsible for brand and generic product portfolio with revenues of approximately US$500m. Prior to Sandoz, he was Vice President of New Business for Nestle Skin Health (parent entity of Galderma) and he was also Vice President of Sales and Marketing for Galderma US, where he led a 300+ person sales and marketing team and was responsible for more than US$1.0b of sales across prescription, over-the-counter and aesthetic dermatology markets.
Executive Vice President, Specialty Brands
Donald has more than 30 years of pharmaceutical industry experience in sales, operations, marketing and managed care. Prior to joining Mayne Pharma in November 2020, Donald served as Franchise Lead and Vice President of Ipsen’s Neuroscience Division and as Chief Executive Officer for eNeura, a medical device company focused on the treatment of migraines and related ailments. Earlier, he served in multiple roles at Allergan over more than 20 years, including Vice President of U.S. Neuroscience Sales during the launch of the chronic migraine indication for BOTOX®; Vice President, U.S. Sales Operations, Vice President, Medical Reimbursement and Vice President Internationals Sales & Marketing for SkinMedica an Allergan company. He also co-promoted two migraine products with the British multinational pharmaceutical company GalaxoSmithKline plc while at Allergan. Mr. Pearl has served on the corporate advisory boards for the American Academy of Neurology, Child Neurology Foundation and the American Academy of Physical Medicine and Rehabilitation.
Executive Vice President, Specialty Products & Patient Solutions
Daniel is responsible for specialty and generic products covering sales and marketing, customer service, pricing and contracts, data and analytical services and channel development. Daniel joined Mayne Pharma in 2015 and has 10 years of healthcare industry experience. Previously, he was Manager for financial planning and analysis at Salix Pharmaceuticals, a specialty pharmaceutical company focused on gastrointestinal disorders.
Executive Vice President and General Counsel
Kate joined Mayne Pharma in March 2013 and has over 20 years of varied legal experience including in corporate, commercial and intellectual property (IP) law and in litigation, spanning multiple jurisdictions. She is responsible for worldwide legal operations, IP, governance, risk and compliance. Prior to joining Mayne Pharma, Kate worked in private practice at Minter Ellison Lawyers, one of the largest Australian-based international law firms, where she worked closely with Mayne Pharma on various agreements and transactions. She has also worked for Shell International in The Hague as IP Counsel.
Vice President, Research and Development
Keith joined Mayne Pharma in 2015 and has more than 20 years of experience in the pharmaceutical industry. Keith has been instrumental in driving Mayne Pharma’s pipeline and the development of branded and generic products. He also worked at Metrics, Inc. for 14 years prior to its acquisition by Mayne Pharma. Keith has served as Vice President of Analytical Services for Mayne Pharma’s CDMO where he led all laboratory functions including laboratory operations, quality control unit, microbiology, analytical development and method validation, stability, and metrology comprising some 180 employees. Prior to this role, he worked at Salix Pharmaceuticals in technical operations supporting R&D, regulatory, and commercial activities. Keith holds degrees in both Chemistry and Business Administration.
Vice President, Group Human Resources
Andy has more than 25 years of experience across all human resource functions. He has held numerous HR consulting roles and was VP of Human Resources and Strategic Partnerships at Crown American Real Estate Investment Trust. Prior to joining Mayne Pharma, he was Associate Professor, Department of Management at East Carolina University. He has published original research in numerous leading research journals on the impact of progressive human resource practices on firm performance outcomes.
Associate General Counsel and Company Secretary
Laura was appointed as the Company Secretary on 26 March 2020. Laura has been with Mayne Pharma since May 2014 and is an experienced commercial lawyer with more than ten years of experience. Prior to joining Mayne Pharma, Laura was a solicitor at global law firm DLA Piper. Laura holds a BCom (Accounting) degree and LLB (Hons) degree from Monash University and is a Graduate member of the Australian Institute of Company Directors.
Vice President, Investor Relations and Communications
Lisa has more than 20 years of experience in the finance industry and has worked with companies including JP Morgan, CVC Asia Pacific and Pacific Brands. Lisa commenced working for Mayne Pharma in 2010 overseeing the investor relations function and was actively involved in all the transformational acquisitions. Lisa has extensive experience in the areas of business development, mergers and acquisitions, corporate strategy, investor relations and corporate governance.